Andrew R. Clamp

Council of Independent Colleges — United States

Medicine · Health Sciences

41h-index10.9kcitations291works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(164), PARP inhibition in cancer therapy(99), BRCA gene mutations in cancer(71), Intraperitoneal and Appendiceal Malignancies(27), Angiogenesis and VEGF in Cancer(23)

Publications289 total

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Future Oncology·2025· 1 citedOpen Access
Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Figure S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025Open Access
Supplementary Table S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Figure S4. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
Supplementary Figure S1. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i>-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
2025Open Access
PHASE 3 ROSELLA (GOG-3073, ENGOT-OV72) TRIAL OF RELACORILANT + NAB-PACLITAXEL VS NAB-PACLITAXEL IN PLATINUM-RESISTANT OVARIAN CANCER: PRIMARY RESULTS AND OUTCOMES IN OLDER PATIENTS
International Journal of Gynecological Cancer·2025
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study
Clinical Colorectal Cancer·2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology·2025
Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
Obstetrical & Gynecological Survey·2025
1138P Low likelihood of tumour homologous recombination deficiency (HRD) in high-grade ovarian carcinomas (HGOCs) harbouring a germline BRIP1 or PALB2 pathogenic variant (PV)
Annals of Oncology·2025
ENCORE: Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis
Gynecologic Oncology·2025
Homologous recombination deficiency in unselected cases of high-grade ovarian carcinoma
Journal of Medical Genetics·2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology·2025· 14 citedOpen Access
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
European Journal of Cancer·2025· 4 citedOpen Access
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
Journal of Clinical Oncology·2025· 3 cited
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
The Lancet·2025· 24 cited
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status
British Journal of Cancer·2025· 1 citedOpen Access
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
2025
page 1 of 15Next →

Frequent Co-authors

Gordon C. Jayson(22), Susana Banerjee(14), Jonathan A. Ledermann(13), Amit M. Oza(13), Nicoletta Colombo(12), Iain A. McNeish(12), Marcia Hall(12), Richard J. Edmondson(9), Sandro Pignata(8), Michael Friedländer(8), Giovanni Scambia(8), David M. O’Malley(8), Andrew Dean(8), Richard T. Penson(7), Carol Aghajanian(7), Anne Floquet(6), Domenica Lorusso(6), Ana Oaknin(6), Peter C.C. Fong(6), Jeffrey C. Goh(6)